rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
It has been reported that KRAS mutations (and to a lesser extent KRAS mutations with the BRAF V600E mutation) negatively affect response to anti-epidermal growth factor receptor (EGFR) mAbs in metastatic colorectal cancer (mCRC) patients, while the biological impact of the EGFR pathway represented by PI3K/PTEN/AKT on anti-EGFR treatment is still not clear.
|
18669866 |
2009 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
It has been reported that KRAS mutations (and to a lesser extent KRAS mutations with the BRAF V600E mutation) negatively affect response to anti-epidermal growth factor receptor (EGFR) mAbs in metastatic colorectal cancer (mCRC) patients, while the biological impact of the EGFR pathway represented by PI3K/PTEN/AKT on anti-EGFR treatment is still not clear.
|
18669866 |
2009 |
rs762936223
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We included 49 patients treated for metastatic colorectal cancer with a combination of 5-fluorouracil and irinotecan; a polymorphism in the UGT1A1 gene (TA repeat in the TATA box) and one in the CES2 gene promoter (830C>G) were studied as potential markers for SN-38 glucuronidation and irinotecan activation, respectively; and the potential activity of CYP3A4 was estimated from cortisol biotransformation into 6beta-hydroxycortisol.
|
18797458 |
2008 |
rs769056296
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We included 49 patients treated for metastatic colorectal cancer with a combination of 5-fluorouracil and irinotecan; a polymorphism in the UGT1A1 gene (TA repeat in the TATA box) and one in the CES2 gene promoter (830C>G) were studied as potential markers for SN-38 glucuronidation and irinotecan activation, respectively; and the potential activity of CYP3A4 was estimated from cortisol biotransformation into 6beta-hydroxycortisol.
|
18797458 |
2008 |
rs879253942
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The ERCC1-118 and MTHFR C677T polymorphisms were associated with progression and severe diarrhoea, respectively, after FOLFOX treatment in mCRC.
|
19672255 |
2009 |
rs1045642
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The aim of the study was to evaluate the influence of the MDR1 C3435T polymorphism on the therapeutic response in 23 patients treated with cetuximab plus irinotecan for irinotecan refractory liver metastatic colorectal cancer considering their KRAS status.
|
19862647 |
2010 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Primary tumours from 144 patients treated for mCRC were assessed for BRAF (V600E) mutation, MSI status and cyclin D1.
|
20485284 |
2010 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Primary tumours from 144 patients treated for mCRC were assessed for BRAF (V600E) mutation, MSI status and cyclin D1.
|
20485284 |
2010 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In this study, 239 samples obtained from 215 patients with metastatic colorectal cancer were tested for the presence of the seven most common mutations in the KRAS gene and the V600E mutation in the BRAF gene.
|
20645028 |
2011 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In this study, 239 samples obtained from 215 patients with metastatic colorectal cancer were tested for the presence of the seven most common mutations in the KRAS gene and the V600E mutation in the BRAF gene.
|
20645028 |
2011 |
rs397517132
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In this study, 239 samples obtained from 215 patients with metastatic colorectal cancer were tested for the presence of the seven most common mutations in the KRAS gene and the V600E mutation in the BRAF gene.
|
20645028 |
2011 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In conclusion, this meta-analysis provides evidence that BRAF V600E mutation is associated with lack of response in wild-type KRAS mCRC treated with anti-EGFR MoAbs.
|
20857202 |
2011 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In conclusion, this meta-analysis provides evidence that BRAF V600E mutation is associated with lack of response in wild-type KRAS mCRC treated with anti-EGFR MoAbs.
|
20857202 |
2011 |
rs397517132
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In conclusion, this meta-analysis provides evidence that BRAF V600E mutation is associated with lack of response in wild-type KRAS mCRC treated with anti-EGFR MoAbs.
|
20857202 |
2011 |
rs112445441
|
|
|
0.090 |
GeneticVariation |
BEFREE |
Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab.
|
20978259 |
2010 |
rs909797662
|
|
|
0.050 |
GeneticVariation |
BEFREE |
Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab.
|
20978259 |
2010 |
rs1217691063
|
|
|
0.010 |
GeneticVariation |
BEFREE |
In this study, the frequency of the MTHFR 677C>T polymorphism is 50% among m-CRC Mexican patients.
|
21044746 |
2010 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
BRAF p.Val600Glu (V600E) somatic mutation is mainly associated with MSS phenotype in metastatic colorectal cancer.
|
21289333 |
2011 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
BRAF p.Val600Glu (V600E) somatic mutation is mainly associated with MSS phenotype in metastatic colorectal cancer.
|
21289333 |
2011 |
rs397517132
|
|
|
0.100 |
GeneticVariation |
BEFREE |
BRAF p.Val600Glu (V600E) somatic mutation is mainly associated with MSS phenotype in metastatic colorectal cancer.
|
21289333 |
2011 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Thus, large-scale KRAS mutation screening is needed for efficient patient management and in the future metastatic colorectal cancer genotyping might also include the detection of the BRAF V600E mutation, which is a very strong negative prognostic factor in colorectal cancer.
|
21516079 |
2011 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Thus, large-scale KRAS mutation screening is needed for efficient patient management and in the future metastatic colorectal cancer genotyping might also include the detection of the BRAF V600E mutation, which is a very strong negative prognostic factor in colorectal cancer.
|
21516079 |
2011 |
rs397517132
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Thus, large-scale KRAS mutation screening is needed for efficient patient management and in the future metastatic colorectal cancer genotyping might also include the detection of the BRAF V600E mutation, which is a very strong negative prognostic factor in colorectal cancer.
|
21516079 |
2011 |
rs112445441
|
|
|
0.090 |
GeneticVariation |
BEFREE |
This retrospective pooled analysis suggests comparable efficacy of cetuximab-based and bevacizumab-based first-line therapy in patients with p.G13D mutant mCRC.
|
22441566 |
2012 |
rs112445441
|
|
|
0.090 |
GeneticVariation |
BEFREE |
Influence of KRAS p.G13D mutation in patients with metastatic colorectal cancer treated with cetuximab.
|
22537608 |
2012 |